German Specialty Pharma Firm Riemser Arzneimittel Bought By AXA Private Equity
This article was originally published in The Pink Sheet Daily
Executive Summary
AXA Private Equity's acquisition of Riemser Arzneimittel is the third change of ownership in the European specialty pharmaceuticals and manufacturing sectors this month, with more likely to follow as buyout specialists seeks the right combination of companies for consolidation.
You may also be interested in...
Cinven's Mercury Pharma Buy Could Spur European Specialty Consolidation
Cinven’s $730 million acquisition of the U.K.-based specialty company Mercury Pharma could act as a platform to consolidate the sector in Europe, suggests the private equity company.
Pipeline Watch: Phase III Readouts in Wilson Disease, Parkinson's Disease And COVID-19
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
AZ's Rare Disease Unit Reports Positive Phase III Results For Copper-Binding ALXN1840
Alexion/AstraZeneca has announced positive top-line results from the Phase III study of ALXN1840 in patients with the rare genetic disorder, Wilson disease, including in patients already on standard-of-care therapies. The compound is ahead of two candidate gene therapies from other companies at early-stage clinical development.